FindTrial
Sign In

Estudio piloto de 24 semanas, doble-ciego aleatorizado, paralelo, controlado con placebo de memantina y terapia del lenguaje restringida en las afasias post-ictus: correlación de los cambios neurofisiológicos con potenciales evocados cognitivos durante la recuperación

Estudio piloto de 24 semanas, doble-ciego aleatorizado, paralelo, controlado con placebo de memantina y terapia del lenguaje restringida en las afasias post-ictus: correlación de los cambios neurofisiológicos con potenciales evocados cognitivos durante la recuperación

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-002337-39-ES
Enrollment
Unknown
Registered
2006-04-04
Start date
2005-03-22
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AFASIA SECUNDARIA A ACCIDENTES CEREBRO-VASCULARES

Interventions

Trade Name: Ebixa (memantina) Product Name: Ebixa (memantina) Product Code: N06DX01 Pharmaceutical Form: Capsule* INN or Proposed INN: CLORHIDRATO DE MEMANTINA Concentration unit: mg milligram(s) Conc

Sponsors

Gabinete Berthier y Martínez, S.L.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Spain

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026